JP2011503063A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503063A5
JP2011503063A5 JP2010533098A JP2010533098A JP2011503063A5 JP 2011503063 A5 JP2011503063 A5 JP 2011503063A5 JP 2010533098 A JP2010533098 A JP 2010533098A JP 2010533098 A JP2010533098 A JP 2010533098A JP 2011503063 A5 JP2011503063 A5 JP 2011503063A5
Authority
JP
Japan
Prior art keywords
medicament
cancer
compound
pharmaceutically acceptable
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010533098A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645667B2 (ja
JP2011503063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012539 external-priority patent/WO2009061446A1/en
Publication of JP2011503063A publication Critical patent/JP2011503063A/ja
Publication of JP2011503063A5 publication Critical patent/JP2011503063A5/ja
Application granted granted Critical
Publication of JP5645667B2 publication Critical patent/JP5645667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010533098A 2007-11-08 2008-11-07 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法 Active JP5645667B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US61/002,583 2007-11-08
US580307P 2007-12-07 2007-12-07
US61/005,803 2007-12-07
US9867608P 2008-09-19 2008-09-19
US61/098,676 2008-09-19
US11206008P 2008-11-06 2008-11-06
US61/112,060 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120238A Division JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Publications (3)

Publication Number Publication Date
JP2011503063A JP2011503063A (ja) 2011-01-27
JP2011503063A5 true JP2011503063A5 (https=) 2011-12-22
JP5645667B2 JP5645667B2 (ja) 2014-12-24

Family

ID=40262072

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010533098A Active JP5645667B2 (ja) 2007-11-08 2008-11-07 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法
JP2014120238A Pending JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120238A Pending JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Country Status (18)

Country Link
US (1) US7968543B2 (https=)
EP (2) EP2596795A1 (https=)
JP (2) JP5645667B2 (https=)
KR (2) KR101578481B1 (https=)
CN (1) CN101835472A (https=)
AR (1) AR069244A1 (https=)
AU (1) AU2008325141B2 (https=)
CA (1) CA2696807C (https=)
CY (1) CY1114853T1 (https=)
DK (1) DK2205244T3 (https=)
ES (1) ES2436266T3 (https=)
HR (1) HRP20131083T1 (https=)
MX (1) MX2010002396A (https=)
PL (1) PL2205244T3 (https=)
PT (1) PT2205244E (https=)
SI (1) SI2205244T1 (https=)
TW (1) TW200924756A (https=)
WO (1) WO2009061446A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2422890T3 (es) * 2006-03-17 2013-09-16 Ambit Biosciences Corporation Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas
CA2696776C (en) * 2007-09-19 2015-12-15 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
CN104447801A (zh) 2009-11-05 2015-03-25 埃姆比特生物科学公司 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
CN104513252B (zh) * 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CN107001283B (zh) 2014-07-31 2021-05-25 国家健康与医学研究院 Flt3受体拮抗剂
KR20250025516A (ko) 2014-12-22 2025-02-21 젠자임 코포레이션 포유류 세포의 배양 방법
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
EP3269367B1 (en) * 2015-03-11 2020-10-07 Riken Therapeutic agent for intractable leukemia
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021180008A1 (zh) * 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US233903A (en) * 1880-11-02 Velocipede
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
ES2422890T3 (es) 2006-03-17 2013-09-16 Ambit Biosciences Corporation Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas
CA2696776C (en) * 2007-09-19 2015-12-15 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Similar Documents

Publication Publication Date Title
JP2011503063A5 (https=)
EP4618991A1 (en) Pharmaceutical combinations and uses thereof
CN102421429B (zh) 癌症治疗用选择性ep4受体拮抗物质
JP2006503919A5 (https=)
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
JP6029808B2 (ja) 併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法
JP2014530852A5 (https=)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2018503610A5 (https=)
CN103533940A (zh) 治疗晚期实体瘤的方法
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2015517523A5 (https=)
CN102065865A (zh) 多发性骨髓瘤治疗
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2010086964A1 (ja) がん治療のための併用療法
JP2025160200A (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
KR20250079033A (ko) Kras 억제제와 조합된 pim 키나제 억제제
CN101357134A (zh) 抗肿瘤效果增强剂和抗肿瘤剂
JP2016502540A5 (https=)
JP2016501884A5 (https=)
JP2023509191A (ja) 癌を治療するための組み合わせ療法
KR20180039084A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 포함하는 약제학적 조성물
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
JP7707329B2 (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬